Ipsen

FDA Approvals Roundup: Qwo, Tremfya, Dysport
FDA Approvals Roundup: Qwo, Tremfya, Dysport
RAPS.org
FDA
drug approvals
Endo International
Qwo
cellulite
Ipsen
Dysport
cerebral palsy
Flag link:
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project
Fierce Pharma
Sanofi
Paul Hudson
David Loew
Ipsen
Pharma CEOs
FerGene
vaccines
Flag link:
Ipsen scraps pivotal trial as partial clinical hold drags on
Ipsen scraps pivotal trial as partial clinical hold drags on
Fierce Biotech
Ipsen
palovarotene
clinical trials
osteochondromas
Flag link:
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
Fierce Pharma
Spark Therapeutics
Ipsen
Rare Diseases
Flag link:
Ipsen takes €669M hit as palovarotene's prospects wither
Ipsen takes €669M hit as palovarotene's prospects wither
Fierce Biotech
Ipsen
palovarotene
Flag link:
Top Companies in Pharm Country Ranked by Revenue
Top Companies in Pharm Country Ranked by Revenue
BioSpace
Connecticut
New York
New Jersey
Pennsylvania
Rhode Island
Merck
Bristol-Myers Squibb
Regeneron
Ipsen
Ovid Therapeutics
Codagenix
Flag link:
Ipsen’s quick fix backfires
Ipsen’s quick fix backfires
EP Vantage
Ipsen
bone disease
palovarotene
Flag link:
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Bloomberg
Ipsen
Somatuline
FDA
fibrodysplasia ossificans progressiva
osteochondromas
Flag link:
Ipsen doubles down on rare bone disease
Ipsen doubles down on rare bone disease
EP Vantage
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
Flag link:
FDA approves Ipsen’s Dysport to treat upper limb spasticity in children
FDA approves Ipsen’s Dysport to treat upper limb spasticity in children
Pharmaceutical Business Review
Ipsen
Dysport
upper limb spasticity
FDA
Flag link:
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Pharmaceutical Business Review
Ipsen
Servier
liposomal irinotecan
pancreatic cancer
Flag link:
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Endpoints
M&A
Ipsen
Clementia Pharmaceuticals
Rare Diseases
Flag link:
FDA approves Cabometyx for liver cancer
FDA approves Cabometyx for liver cancer
BioCentury
Exelixis
Ipsen
Cabometyx
liver cancer
FDA
Flag link:
With New HQ, Ipsen to Rapidly Expand North American Presence
With New HQ, Ipsen to Rapidly Expand North American Presence
BioSpace
Ipsen
Kendall Square
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
Flag link:
Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs
Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs
Endpoints
biotech
Boston
Kendall Square
Ipsen
hirings
Flag link:
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Flag link:

Pages